pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioSpace·1h ago·1 min read
save

Career setbacks offer data points, not definitive verdicts, says executive coach

Sep 9, 2026·read at BioSpace ↗Neutral

Angela Justice, an executive coach, describes how a sudden layoff can feel like a verdict but is really just a data point.

She warns that people often turn the specific lesson from a setback into a broad rule, such as believing loyalty is foolish after a layoff, which can limit future opportunities.

Justice advises professionals to reflect on the actual event without overgeneralizing, using the experience to inform choices while avoiding rigid rules that may hinder career growth.

source

This writeup was produced by pharmadog from original reporting by BioSpace.

Original headline: “A career setback is a data point, not a verdict”

read at BioSpace ↗
1,131 words · retrieved 29m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 3h agoBeyond China: Five other overseas destinations for biopharma dollarsBioSpace
  • 3h agoSteady stream of crossover rounds stock biotech's IPO pipelineBioSpace
  • 17h agoInhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancerBioSpace
  • 17h agoStructure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data dropBioSpace
  • 17h agoNovo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’BioSpace